SCHEDULE: BlackRock Amends Stake in Jasper Therapeutics, Reports 1.5% Beneficial Ownership

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.5% beneficial ownership stake in Jasper Therapeutics Inc. as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 225,605 shares of Jasper Therapeutics Inc. common stock.
• This ownership represents 1.5% of the total outstanding common shares of Jasper Therapeutics Inc.
• BlackRock holds sole voting power over 225,205 shares and sole dispositive power over 225,605 shares.
• The filing is an Amendment No. 1 to a previously filed Schedule 13G.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It indicates a routine, passive investment by an institutional holder.

Positives

• No specific positives related to company performance or strategy are typically disclosed in a Schedule 13G filing, which primarily reports passive ownership.

Negatives

• No specific negatives related to company performance or strategy are typically disclosed in a Schedule 13G filing, which primarily reports passive ownership.

Risks

• This filing does not detail specific risks related to Jasper Therapeutics Inc.'s operations or financial health; it is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Jasper Therapeutics Inc.'s future outlook.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

Schedule 13G filings are standard disclosures by institutional investors like BlackRock, indicating passive ownership stakes of less than 5% (or between 5% and 20% under certain conditions) in publicly traded companies. This filing indicates BlackRock's continued, passive investment in Jasper Therapeutics Inc., reflecting a routine portfolio holding rather than an active strategic move to influence company control.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake.
• Employees, Customers, Suppliers, Creditors: No direct impact from this beneficial ownership filing.

Next Steps

• No specific future actions or milestones for Jasper Therapeutics Inc. are mentioned in this filing. BlackRock will continue to monitor its investment and file amendments as required by changes in its ownership stake.

Key Dates

Keywords

Jasper Therapeutics Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Stake